Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · MAXCYTE, INC. (MXCT)

MaxCyte Q2 revenue falls 15% to $7.3 million; net loss narrows to $8.9 million

Mixed Impact 3 of 5 earnings Written later

MaxCyte reported second-quarter 2026 revenue of $7.3 million, down 15% from a year earlier, while its net loss narrowed to $8.9 million from $12.4 million. The company reiterated full-year 2026 revenue guidance of $30 million to $32 million, so shareholders get a smaller loss alongside a shrinking top line.

Key points

  • Total revenue $7.3 million vs. $8.5 million in Q2 2025, down 15%; core revenue down 21% to $6.5 million
  • Net loss $8.9 million vs. $12.4 million a year earlier; operating expenses $15.8 million vs. $21.2 million
  • Full-year 2026 revenue guidance of $30 million to $32 million reiterated; year-end cash expected to be at least $130.5 million
  • Repurchased about $5.5 million of common stock to date under a $10 million buyback; cash and investments $141.9 million at June 30, 2026

The filing

CompanyMAXCYTE, INC. (MXCT)
Form8-K, current report
Filed with the SECAug 12, 2026, 4:14 PM ET
Accession number0001104659-26-094886

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.